OCT devices hold promise

Article

Improved imagery could help physicians learn more about diseases and treatment response

New optical coherence tomography (OCT) devices are in development with the goal of expanding the utility of OCT in the clinic by providing better resolution, faster speed, and software to help clinicians better understand the nuances of diseases and how they respond to therapy. Dr Jay S. Duker looked at the past, present and future of the technology during the Retina Subspeciality Day at the annual meeting of the American Academy of Ophthalmology.

The first OCTs that became commercially available in 1996 were time-domain (TD) instruments. Those reached their pinnacle in 2002 when the Stratus OCT was introduced by Zeiss. That instrument, which had 10 μm axial resolution and obtained 400 axial scans per second, remained the state-of-the-art technology until recently.

Over the past decade, many new OCT instruments have become available that are all based on Fourier-domain detection. Spectral-domain (SD) OCT became commercially available in 2006 and swept-source OCT is being used in research but is not yet commercially available. SD-OCT is faster than TD-OCT and can obtain from 20000 to 52000 scans per second. It also has a broader band width that increases the axial resolution from 4 to 7 μm.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Colman Cawe, director of fundraising and communications, Orbis UK
Related Content
© 2023 MJH Life Sciences

All rights reserved.